Cabotegravir/Rilpivirine

卡替拉韦/利匹韦林

Report date: 2022/09/21 09:27:47
NME

Base Information

Drug NameCabotegravir/Rilpivirine
Drug Alias NameRilpivirine/Cabotegravir卡博特韦+利匹韦林Cabotegravir and RilpivirineCabenuva
ClassificationSmall molecules
Mechanisms of ActionReverse transcriptase inhibitorsHIV integrase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsPuerperal DisordersHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2020/03/18
Country/TerritoryCanadaBotswanaUnited States +[12] 
CombinationsYes CabotegravirRilpivirine Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesViiv HealthcareJanssen Pharmaceutical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcJanssen Pharmaceuticals IncUniversity College London +[5] 
Inactive CompaniesYale UniversityAllegheny Singer Research InstituteNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHIV Infections
Inactive IndicationsPuerperal Disorders

Other Information

ATC CodeJ05AR
Related LinksN/A